The Swiss molecular diagnostics company, Biocartis SA, has raised €30 million in a Series B financing round which was supported by the new investors, Johnson & Johnson Development Corp and the Debiopharm Group. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
